[go: up one dir, main page]

WO2008149428A1 - Therapeutic agent and preventive agent for autoimmune disease, inflammation and nerve disease - Google Patents

Therapeutic agent and preventive agent for autoimmune disease, inflammation and nerve disease Download PDF

Info

Publication number
WO2008149428A1
WO2008149428A1 PCT/JP2007/061376 JP2007061376W WO2008149428A1 WO 2008149428 A1 WO2008149428 A1 WO 2008149428A1 JP 2007061376 W JP2007061376 W JP 2007061376W WO 2008149428 A1 WO2008149428 A1 WO 2008149428A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
inflammation
agent
therapeutic agent
hyaluronidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/061376
Other languages
French (fr)
Japanese (ja)
Inventor
Akira Asari
Tadahiko Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GLYCOSCIENCE LABORATORIES Inc
Original Assignee
GLYCOSCIENCE LABORATORIES Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GLYCOSCIENCE LABORATORIES Inc filed Critical GLYCOSCIENCE LABORATORIES Inc
Priority to PCT/JP2007/061376 priority Critical patent/WO2008149428A1/en
Publication of WO2008149428A1 publication Critical patent/WO2008149428A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

An agent containing a hyaluronidase as an active ingredient is used for prevention or treatment. The hyaluronidase is not particularly limited and any can be used as long as it has an activity to degrade hyaluronic acid. In the invention, for example, a hyaluronidase having the following polypeptide (a) or (b): (a) a polypeptide consisting of an amino acid sequence represented by SEQ ID NO: 1 (b) a polypeptide consisting of an amino acid sequence in which one or more amino acids have been substituted, deleted, added or inserted in the amino acid sequence represented by SEQ ID NO: 1 and having an activity to degrade hyaluronic acid.
PCT/JP2007/061376 2007-06-05 2007-06-05 Therapeutic agent and preventive agent for autoimmune disease, inflammation and nerve disease Ceased WO2008149428A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2007/061376 WO2008149428A1 (en) 2007-06-05 2007-06-05 Therapeutic agent and preventive agent for autoimmune disease, inflammation and nerve disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2007/061376 WO2008149428A1 (en) 2007-06-05 2007-06-05 Therapeutic agent and preventive agent for autoimmune disease, inflammation and nerve disease

Publications (1)

Publication Number Publication Date
WO2008149428A1 true WO2008149428A1 (en) 2008-12-11

Family

ID=40093264

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/061376 Ceased WO2008149428A1 (en) 2007-06-05 2007-06-05 Therapeutic agent and preventive agent for autoimmune disease, inflammation and nerve disease

Country Status (1)

Country Link
WO (1) WO2008149428A1 (en)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01500997A (en) * 1986-09-30 1989-04-06 ビオヘミー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Use of hyaluronidase
JPH06502840A (en) * 1989-10-27 1994-03-31 ケース ウェスタン リザーブ ユニバーシティ Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
JPH11147837A (en) * 1997-08-22 1999-06-02 Seikagaku Kogyo Co Ltd Therapeutic agent for discogenic hernia
JP2002509542A (en) * 1997-07-09 2002-03-26 ジョンソン，セシリア Use of hyaluronidase in the manufacture of a medicament for treating inflammation
JP2002322089A (en) * 2001-04-24 2002-11-08 Seikagaku Kogyo Co Ltd Nitrogen oxide production inhibitor
WO2004103299A2 (en) * 2003-05-16 2004-12-02 Acorda Therapeutics, Inc. Compositions and methods for the treatment of cns injuries
WO2004110359A2 (en) * 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Fusion proteins for the treatment of cns
JP2005500375A (en) * 2001-08-13 2005-01-06 ユニバーシティ・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド Materials and methods for promoting neural tissue repair
WO2005074655A2 (en) * 2004-01-30 2005-08-18 Emory University Materials and method for promotion of nerve regeneration
JP2005526740A (en) * 2002-03-04 2005-09-08 ケンブリッジ・ユニバーシティ・テクニカル・サービシーズ・リミテッド Treatment of central nervous system damage
JP2007153797A (en) * 2005-12-05 2007-06-21 Toshitsu Kagaku Kenkyusho:Kk Therapeutic agent and preventive agent of autoimmune disease, inflammation, and nervous disease

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01500997A (en) * 1986-09-30 1989-04-06 ビオヘミー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Use of hyaluronidase
JPH06502840A (en) * 1989-10-27 1994-03-31 ケース ウェスタン リザーブ ユニバーシティ Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
JP2002509542A (en) * 1997-07-09 2002-03-26 ジョンソン，セシリア Use of hyaluronidase in the manufacture of a medicament for treating inflammation
JPH11147837A (en) * 1997-08-22 1999-06-02 Seikagaku Kogyo Co Ltd Therapeutic agent for discogenic hernia
JP2002322089A (en) * 2001-04-24 2002-11-08 Seikagaku Kogyo Co Ltd Nitrogen oxide production inhibitor
JP2005500375A (en) * 2001-08-13 2005-01-06 ユニバーシティ・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド Materials and methods for promoting neural tissue repair
JP2005526740A (en) * 2002-03-04 2005-09-08 ケンブリッジ・ユニバーシティ・テクニカル・サービシーズ・リミテッド Treatment of central nervous system damage
WO2004103299A2 (en) * 2003-05-16 2004-12-02 Acorda Therapeutics, Inc. Compositions and methods for the treatment of cns injuries
WO2004110359A2 (en) * 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Fusion proteins for the treatment of cns
WO2005074655A2 (en) * 2004-01-30 2005-08-18 Emory University Materials and method for promotion of nerve regeneration
JP2007153797A (en) * 2005-12-05 2007-06-21 Toshitsu Kagaku Kenkyusho:Kk Therapeutic agent and preventive agent of autoimmune disease, inflammation, and nervous disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BACK S.A. ET AL.: "Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation", NAT. MED., vol. 11, no. 9, 2005, pages 966 - 972 *
BOCK E. ET AL.: "Possibilities of a new method of symptomatic therapy of multiple sclerosis", CESK NEUROL., vol. 22, 1959, pages 257 - 259, XP003024607 *
GOURIE-DEVI M. ET AL.: "Intrathecal hyaluronidase treatment of chronic spinal arachnoiditis of noninfective etiology", SURG. NEUROL., vol. 22, no. 3, 1984, pages 231 - 234, XP023116533 *
MASTRONARDI F.G. ET AL.: "Molecules affecting myelin stability: a novel hypothesis regarding the pathogenesis of multiple sclerosis", J. NEUROSCI. RES., vol. 80, no. 13, 2005, pages 301 - 308 *
NAKAHARA H.: "Chusu Shinkei Zuisho Keisei Kiko no Kaimei - Tahatsusei Kokasho no Chiryo e Mukete", IGAKU NO AYUMI, vol. 206, no. 3, 2003, pages 985 - 986 *
WEISS L. ET AL.: "Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody", PROC. NATL. ACAD. SCI. U.S.A., vol. 97, no. 1, 2000, pages 285 - 290, XP055237279, DOI: doi:10.1073/pnas.97.1.285 *

Similar Documents

Publication Publication Date Title
EP4461811A3 (en) Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
WO2005023866A3 (en) Peptides that inhibit complement activation
WO2004009558A3 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
EP2455462A3 (en) Lipase variants for pharmaceutical use
WO2008063382A3 (en) Antagonists of pcsk9
WO2008057457A3 (en) Antagonists of pcsk9
WO2008057458A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
AU2728900A (en) Multi-purpose acid compositions
WO2008070670A3 (en) Enhanced immediate release formulations of topiramate
WO2009025116A1 (en) Cdh3 peptide and medicinal agent comprising the same
WO2007102686A8 (en) Peptides having activities of insulin like growth factor-1 and their uses
WO2007081824A3 (en) Fibrillation resistant proteins
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
MX2008009493A (en) Novel peptide and use thereof.
WO2019045248A3 (en) Peptide exhibiting wrinkle-improving activity and uses thereof
SG10201406288SA (en) Multimeric forms of antimicrobial peptides
WO2010103070A3 (en) Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
CA2549185A1 (en) Peptide inhibiting angiotensin converting enzyme
WO2010086867A3 (en) Peptides, pharmaceutical compositions comprising same and uses thereof
WO2008149428A1 (en) Therapeutic agent and preventive agent for autoimmune disease, inflammation and nerve disease
AU2003251728A1 (en) Placental growth factor as a target for the treatment of osteoporosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07744728

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07744728

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP